In his letter to the editors of Oncogene, Dr Sehgal (2010, this issue) states 'ythe recent articles of Walter et al. (2009) and Sullivan et al. (2009) confirm and recapitulate the concepts about the involvement of IL-6 in breast cancer pathobiology already enunciated by the Tamm and Revel laboratories between 15 to 20 years ago, but without acknowledgement of the existence of that extensive prior literaturey'. While we apologize for the inadvertent omission of Drs Tamm and Sehgal's earlier work ) on interleukin-6 (IL-6), we disagree with Dr Sehgal's suggestion that our reported findings are merely a duplication of the earlier work carried out by him and Dr Tamm.
Our study investigated the impact of adipose stromal cells (ASCs) on the migratory behavior and invasiveness of breast cancer cells, in particular estrogen receptornegative breast cancer cells. ASCs have only recently been discovered and characterized, and it had not been the subject of any published studies by Drs Tamm and Sehgal. Importantly, we wish to point out two significant aspects of our work. First, we demonstrate that ASCs from cancer-free individuals have an intrinsic capability of promoting tumor cell migration and invasion, which may provide a molecular explanation for the obesity-associated cancer risk. Second, we identify a previously unappreciated link between the cofilin-mediated pathway and interleukin-6 expression in ASCs. Given that the cofilin-mediated pathway in tumor cells is known to have an important role in tumor invasion and metastasis, our work raises the distinct possibility that simultaneous inhibition of the same pathway in tumor and stromal compartments may provide an attractive therapeutic strategy for cancer treatment. The novelty of our findings, which is clearly presented in our publication, sets our work apart from the published studies by Tamm and Sehgal. The fact that our mechanistic investigation ultimately connects the tumor-promoting effects of ASCs and the cofilin pathway with a well-studied cytokine should not serve as the basis for dismissing the overall significance of our work.
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Response to Sehgal
Oncogene ( We would like to thank Dr Sehgal for his dissenting opinion on the novelty of our recent publication in the 2009 Oncogene issue (Sullivan et al., 2009) , and we recognize the importance of the pioneering work by Tamm, Sehgal, and colleagues (Tamm et al., 1989 (Tamm et al., , 1991a (Tamm et al., , b, 1994a (Tamm et al., , b, 1998 Krueger et al., 1991; Sehgal and Tamm, 1991) for many aspects of interleukin-6 (IL-6) biology. However, we disagree with the assertions made by Dr Sehgal that a previous body of work has established a phenotypic or a biological signature of epithelial-mesenchymal transition (EMT).
First and foremost, we feel it is prudent to clearly define the process of EMT. For example, is it sufficient to define EMT as a change in cellular localization of E-cadherin in 2D culture with the observed biological responses of cell detachment and decreased cell proliferation? As detailed in the introduction of our 2009 Oncogene publication (Sullivan et al., 2009), we cited multiple studies that focused on the EMT process in cancer. One of these citations, a recent review by Yang and Weinberg, details the EMT processes associated with development and cancer (Yang and Weinberg, 2008) . From this review, a historical and current definition of EMT is described. We will summarize the details and definitions that are pertinent for this discussion. As stated, EMT was defined in the 1980s following a series of 3D culture studies (Greenburg and Hay, 1982 , 1986 , 1988 . These studies provided a first definition of EMT based on changes in cellular properties that altered the functional relationship between epithelial cells, the underlying basal lamina and the extracellular matrix (ECM). These properties included epithelial cell elongation and acquisition of a mesenchymal morphology (pseudopodia/filapodia), cellcell detachment (epithelial cell disassociation) and cell migration. Subsequent cellular and molecular cell studies have further refined the definition and process of EMT. EMT is defined as a dynamic process characterized by morphological changes (epithelial to mesenchymal) associated with distinct changes in cell differentiation markers, including a loss of cell-cell junctions (for example, CDH1), changes in cytokeratin intermediate filaments, acquisition of mesenchymal markers (for example, Vimentin, N-cadherin) and expression of EMT-inducing transcription factors (for example, Twist, Snail, Slug). In addition, functional changes in epithelial cells that confer an ability to invade across the ECM are a functional hallmark of EMT. Epithelial cells, which undergo EMT, demonstrate altered cellular characteristics, acquire enhanced motility/invasiveness and develop unique interactions with the extracellular microenvironment (for example, ECM).
Dr Sehgal asserts that a previous work by him and others has already defined an IL-6-dependent EMT process in breast epithelial tumor cell lines. Further, Dr Sehgal proposes that our current work lacks novelty owing to the replication of his previous work. To clearly establish the novelty of our current work and the disparities between our respective studies, we discuss below the similarities and differences between our work and that referred to by Dr Sehgal.
Comparison of experimental approaches
The major conclusion from the early works of Tamm and Sehgal was that IL-6 disrupts cellular localization of cell surface E-cadherin (CDH1) (Tamm et al., 1994) , which corresponds to descriptive observations of cellular morphogenic alterations consistent with EMT or 'fibroblastoid conversion' (Tamm, , 1994 . Experiments in these early publications were carried out in 2D tissue culture in the presence of serum and estradiol, and it is in these experimental conditions that Tamm and Sehgal reported stable E-cadherin levels or expression and relocalization of E-cadherin away from the cell membrane. This is in contrast to what we report in our stable IL-6/2D model (Figure 2 ), in 3D lamininrich basement membrane extract (BME) (Figure 1 ) and in vivo ( Figure 5) (Sullivan et al., 2009) , in which we demonstrate dramatic reductions in E-cadherin expression. Another major difference between the historical studies and ours is the utilization of estradiol by Sehgal and colleagues. Estradiol counteracts IL-6-driven EMT by stabilizing expression of the cdh1 gene downstream of MTA3 (Kang and Massague, 2004) , which, in addition to the use of 2D/plastic systems, may account for why Tamm and Sehgal did not observe decreases in E-cadherin expression following IL-6 exposure.
EMT phenotype
The EMT phenotype as described in the work cited by Dr Sehgal was primarily based on empirical and quantitative observations of cell rounding and detachment from plastic dishes after IL-6 exposure. However, biological consequences linking enhanced invasion and growth to EMT were not observed nor described. In fact, the authors concluded that IL-6 promotes enhanced motility and decreased cellular proliferation in breast epithelial tumor cells. Although decreased E-cadherin expression is one of the most cited phenotypic changes associated with EMT, this was not observed by Sehgal and colleagues. In contrast, their body of work found that IL-6 exposure led to stable expression of E-cadherin protein, which was subsequently relocalized away from the cell membrane.
EMT-associated increases in invasion
We did not report nor discuss changes in adherence to plastic dishes or cell-cell interactions, as our studies were carried out in serum-free, phenol red-free 3D BME cultures and in vivo. It should be noted that serum-free growth in BME is not equivalent to serum starvation in 2D. BME alone sustains breast tumor cell growth for up to 10-12 days (Sasser et al., 2007a, b) . Unlike the early work cited by Dr Sehgal, we did not report on changes in tumor cell motility; rather we cited changes in invasion through BME, which has been described as a functional hallmark of EMT (Yang and Weinberg, 2008) . We demonstrated that IL-6 drives a phenotypic profile consistent with EMT (Figures 2 and 5 ) and that this EMT phenotype, driven by IL-6, was associated with enhanced breast tumor cell growth and invasion (Figures 3 and 5) . In our study (Sullivan et al., 2009) , unlike the previous work cited by Dr Sehgal, we demonstrated that IL-6-driven EMT promotes decreased cdh1 (and E-cadherin protein) and increased n-cadherin, vimentin, snail and twist (that is, a molecular EMT profile), and that this phenotypic change is associated with enhanced breast tumor cell growth and invasion (that is, not enhanced plastic detachment/motility and decreased cell proliferation). Furthermore, we demonstrated a potent EMT-driving autocrine loop via Twist expression, which was again not described in the previous work cited by Dr Sehgal.
EMT-associated increases in cell proliferation or tumor growth
The conclusion from Dr Tamm and Dr Sehgal's previous work was that IL-6 decreases adherence to neighboring cells, increases tumor cell motility and decreases tumor cell DNA synthesis (that is, decreased cell proliferation). These observations are thematic throughout the early Tamm and Sehgal studies cited and are notably in stark contrast to our findings. Results similar to those of Tamm and Sehgal (for example, diminished proliferation) using 2D models were reproduced by Badache and Hynes (2001) . Dr Sehgal suggests that 'IL-6 inhibited, enhanced or had no effect on epithelial cell proliferation depending on cell type and subclone characteristics'. This statement is misleading and confusing. Krueger et al. (1991) demonstrated that IL-6 enhanced keratinocyte proliferation and inhibited breast epithelial cell proliferation (ZR-75-1 and T47D), which is directly the opposite of what we have observed and reported for these and other estrogen receptor apositive breast cancer cell lines in 3D ECM models (Sasser et al., 2007a, b) . We have established a strong association between chronic IL-6 exposure and EMT, which leads to a molecular EMT phenotype, enhanced invasion and enhanced growth (Sullivan et al., 2009 ). Furthermore, we have shown that IL-6 is a potent growth factor for breast and ovarian epithelial tumor cell lines in 3D and in vivo models (Sasser et al., 2007a, b; Studebaker et al., 2008; Spaeth et al., 2009) . A detailed description of 2D/3D disconnects that likely accounts for the discrepancy between our work and that of Dr Badache/Haynes as well as that of Dr Tamm/Sehgal can be found in those citations. A missing component of our previous work was the mechanism of action that linked IL-6-dependent signaling in relevant tumor microenvironments with enhanced tumor cell growth and invasion. These processes were clearly defined in our study, and nowhere in Dr Sehgal's cited work are these biological consequences of IL-6-driven EMT described.
Although the previous work from the laboratories of Dr Tamm and Dr Sehgal are interesting, we disagree with Dr Sehgal's assertion that our current work lacks novelty. Perhaps if we had expanded the discussion in our publication, we could have addressed the many discrepancies between our work and that of Dr Sehgal and colleagues, but instead, we opted to focus on the clinical implications of IL-6 in breast cancer based on our current and recent findings.
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